Email Newsletters

Life Sciences

Nuclea Raises $5M In Latest Funding Round

Nuclea Biotechnologies Inc., which has operations in Worcester, announced that it has closed its first Series C...

HBIO Reports 5% Revenue Growth In Q2

Holliston-based Harvard Bioscience Inc. (HBIO) said its revenues were up 5 percent in the second quarter, to $28.5...

Karyopharm’s Cancer Killer

A new drug can take between 11 and 14 years to bring to market, according to the...

Nuclea Buys Patents

Nuclea Biotechnologies Inc., which has offices in Worcester and Pittsfield, said it has purchased six patents and...
ADVERTISEMENT

Life Sciences Center Announces Open Solicitation For Capital Projects

High schools, academic and research institutions, business incubators and non-profits across Massachusetts are invited to apply for...

ACT Treats Fourth Patient With Higher Cell Therapy Dosage

Advanced Cell Technology of Marlborough has treated its fourth patient in its U.S. clinical trial for Stargardt's...

In Search Of A Niche: 5 Factors Experts Say Can Push Central Mass Forward In Life Sciences

The efforts to turn Central Massachusetts into a life sciences epicenter to rival — or depending who...

Carving Out A Niche In Regenerative Medicine

Holliston-based Harvard Bioscience rolled out a bioreactor in 2010 that's now playing a vital role in the...
ADVERTISEMENT

Holliston Firm Plays Part In Russian Clinical Trial

Harvard Bioscience Inc., a Holliston-based life sciences products manufacturer, said one of its products was used for...

Psychemedics Gets FDA Clearance For Hair Analysis Drug Test

Acton-based drug test maker Psychemedics Corp. announced it has received clearance from the Food & Drug Administration...
ADVERTISEMENT

Latest Stories

More Business News
ADVERTISEMENT

Thought Leadership

More Thought Leadership

Career Opportunities

More Jobs | Submit a Job
More Events | Submit an Event

Get our email newsletter

Stay up-to-date on the companies, people and issues that impact businesses in Central Massachusetts.

Close the CTA